Nicholas Johnson is a Clinical Trials Statistician at Imperial Clinical Trials Unit (ICTU), School of Public Health with over 6 years experience in clinical trials.
Whilst primarily part of the Cardiovascular/Respiratory trial team, he has worked on studies across a number of therapeutic areas. He has also had experience in Phase 1 Pharmacokinetic (PK) analysis. Current studies include; HOPE-HF, DeVENT, MALIBO and RIO whilst past studies include AVATAR-AF, Endobarrier and SERCA-LVAD.
Nicholas completed his BSc in Statistics and Computing from the Open University in 2011 and subsequently obtained an MSc (Merit) in Statistics from the University of Kent in 2013.
A keen runner and cat-lover, Nicholas has been with ICTU since October 2015.
et al., 2020, A duodenal sleeve bypass device added to intensive medical therapy for obesity with type 2 diabetes: a RCT, Efficacy and Mechanism Evaluation, Vol:7, ISSN:2050-4365, Pages:1-130
et al., 2020, The effect of a duodenal-jejunal bypass liner on lipid profile and blood concentrations of long chain polyunsaturated fatty acids, Clinical Nutrition, ISSN:0261-5614
et al., 2020, Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device – the SERCA-LVAD TRIAL, Gene Therapy, Vol:27, ISSN:0969-7128, Pages:579-590
et al., 2020, Evidence of unexplained discrepancies between planned and conducted statistical analyses: a review of randomized trials, Bmc Medicine, Vol:18, ISSN:1741-7015
et al., 2020, The effect of a duodenal-jejunal bypass liner device (Endobarrier (R)) on lipid profile and blood concentrations of long chain polyunsaturated fatty acids, 11th Annual Scientific Meeting of the British-Obesity-and-Metabolic-Surgery-Society (BOMSS), SPRINGER, Pages:S16-S17, ISSN:0960-8923